Lördag 27 December | 03:16:26 Europe / Stockholm

Kalender

Est. tid*
2026-08-28 08:00 Kvartalsrapport 2026-Q2
2026-04-02 N/A Årsstämma
2026-03-06 08:00 Bokslutskommuniké 2025
2025-08-28 - Kvartalsrapport 2025-Q2
2025-04-07 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2025-04-04 - Årsstämma
2025-03-07 - Bokslutskommuniké 2024
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-05 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2024-04-04 - Årsstämma
2024-03-07 - Bokslutskommuniké 2023
2023-08-25 - Kvartalsrapport 2023-Q2
2023-03-31 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2023-03-30 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-04-06 - X-dag ordinarie utdelning AIFORIA 0.00 EUR
2022-04-05 - Årsstämma
2022-03-02 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorInformationsteknik
IndustriProgramvara
Aiforia Technologies utrustar patologer och forskare i prekliniska och kliniska laboratorier med programvara för att översätta bilder till upptäckter, beslut och diagnoser. Bolagets produkter och tjänster används för medicinsk bildanalys, över en mängd olika områden såsom onkologi samt neurovetenskap. Aiforia Technologies har sitt huvudkontor i Finland.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-17 08:00:00

Aiforia launches next-generation AI technology platform

Aiforia Technologies Plc, Press Release, December 17, 2025 at 9:00 a.m. EET

Aiforia Technologies Plc announces the expansion of its AI technology platform featuring the Vision Transformer architecture. Leveraging patent-pending innovation, Aiforia’s new Foundation Engine overcomes the common hurdles faced with foundation models. It delivers rapid execution and cost-efficient processing for both AI training and image analysis, while still benefiting from the large, diverse datasets inherent to foundation models. With this launch, Aiforia not only adopts the Vision Transformer technology into its own product development but also makes it available to users of its unique AI training tool, Aiforia® Create.

Aiforia’s Foundation Engine leverages foundation models, pre-trained on vast image datasets, and combines them with task-specific annotations provided by pathologists. This optimized combination significantly accelerates AI model development, resulting in robust models that generalize effectively across diverse environments. AI models built with Aiforia’s Foundation Engine maintain the high level of transparency of previous generations, offering visual, pixel-level analysis and quantitative data alongside sample scoring based on the AI-generated results.

“Harnessing this next-generation AI technology provides us with a significant competitive edge by accelerating our clinical AI model development and enhancing the robustness of our AI models. These enhancements are now also integrated into Aiforia® Create, our distinct AI training tool, which provides pathologists and scientists with an unparalleled environment for developing their own AI models for diverse image analysis applications”, says Jukka Tapaninen, CEO of Aiforia.

Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/

 

Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

 

About Aiforia 

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.

Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient. 

Find out more at www.aiforia.com